Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to $17.8 million.

  • 4D Molecular Therapeutics' Cash from Investing Activities fell 3488.15% to $17.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.9 million, marking a year-over-year increase of 11357.87%. This contributed to the annual value of -$302.4 million for FY2024, which is 36135.92% down from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Cash from Investing Activities stood at $17.8 million for Q3 2025, which was down 3488.15% from -$13.9 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Cash from Investing Activities ranged from a high of $57.5 million in Q2 2022 and a low of -$263.3 million during Q1 2024
  • Over the past 5 years, 4D Molecular Therapeutics' median Cash from Investing Activities value was -$642000.0 (recorded in 2021), while the average stood at -$17.9 million.
  • In the last 5 years, 4D Molecular Therapeutics' Cash from Investing Activities tumbled by 3993094.56% in 2021 and then skyrocketed by 789755.77% in 2022.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Cash from Investing Activities stood at -$32.3 million in 2021, then decreased by 10.8% to -$35.8 million in 2022, then soared by 81.32% to -$6.7 million in 2023, then skyrocketed by 205.64% to $7.1 million in 2024, then skyrocketed by 151.85% to $17.8 million in 2025.
  • Its last three reported values are $17.8 million in Q3 2025, -$13.9 million for Q2 2025, and $31.9 million during Q1 2025.